anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preterm birth (\<37 weeks gestation) occurs in 10% of all pregnancies worldwide and the optimal way to feed a newborn preterm infant, when breast-feeding is impossible, is not clear. Excessive enteral feeding predisposes to various complications and necrotizing enterocolitis (NEC) that occur in 7% of preterm infants born with less than 1500 g body weight. Early feeding with small volumes of milk is applied to promote GIT maturation and add some nutrients and energy. It is assumed that early feeding allows more rapid advancement to full enteral feeding (EN, e.g 120-160 ml/kg/d) and weaning from parenteral nutrition (PN). This is important to reduce PN-related complications (e.g. sepsis) and to better stimulate body and organ (e.g. gut, brain) development. However, it remains unclear what is the best milk diet when mother's own milk (MM) is not available. Infant formula (IF) and banked human donor milk (DM) are the most frequently used alternatives to MM. MM is superior to IF in promoting feeding tolerance, intestinal function, and NEC resistance in preterm infants. Feeding with DM is also believed to be beneficial, relative to IF, although this pasteurized milk obtained from mothers later in lactation may be less beneficial, relative to the first milk, colostrum. There are differences in the amount and composition between human colostrum and bovine colostrum (BC), but relative to mature human milk, BC contains higher amounts of protein, growth factors and immuno-regulatory components (e.g. immunoglobulins). Large amount of protein in BC provides higher enteral protein intake and may enable a reduction in the use of PN and central venous catheters, and hereby reduced risk of infection. Also this may lead to reduced weight loss and improved growth of the brain and the body. In addition, maturational and NEC-protective effects of BC have repeatedly been documented in preterm pigs when BC is used as the first diet after birth. The investigators therefore plan to investigate whether using BC as nutrition for preterm infants in the first weeks of life is safe, tolerable, and helps to provide nutrients and gut maturation , when MM is not in sufficient amounts or not available.
Patients will receive a pre-operative CBCT examination. Implants will be inserted using freehand drilling protocol. The implants will be placed using flapless technique with the reference of neighboring teeth and 3D radiographic information.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and has complex genetic underpinnings. Despite advancements in treatment, mortality of AF patients remains high. This review discusses the genetic basis of AF and its implications for diagnosis and therapy. Although AF pathology has long been known to include a hereditary component, the first genes associated with AF were not identified until the early 2000s. Subsequent research with genome-wide association studies (GWAS) has implicated other genes and numerous genetic variants in AF. These studies have revealed nearly 140 different regions in the DNA with genome-wide significance associated with AF. In addition to common variants, rare variants with large effects have also been identified. The integration of these genetic findings into clinical practice holds promise for improving AF diagnosis and treatment, moving us closer to precision medicine. However, challenges remain, including the need for more diverse genetic data of non-European ancestry and improved genetic analyses of responses to AF therapy.
An image-recognition assisted claim system includes an image capturing module, a recognition unit, a processing unit, and a storage unit. The image capturing module captures an image of a claim document to generate a claim document image file corresponding to the claim document. The recognition unit recognizes a pathological name in the claim document image file. The processing unit is electrically connected to the image capturing module and the recognition unit and obtains a corresponding international disease classification code according to the pathological name. The storage unit is electrically connected to the processing unit for storing the international disease classification code, and automatically recognizing the pathological name and the international disease classification code. Thereby, the working time of claimants can be dramatically reduced.
The invention relates to a novel cough-relieving medicine prescription. According to the prescription, loquat leaf, opium poppy peel, sessile stemona root tuber, whiteflower hogfennel root, balloonflower root, and white mulberry root-bark are adopted as main materials; a proper amount of sugar stevia leaf is added as a sweet flavoring. The medicine is a sugar-free cough-relieving medicine aiming at diabetes mellitus patients. The medicine can be prepared into tablets, buccal tablets, capsules and soft capsules, granules, syrups, liquids, micro-pills, microspheres, pellets, and the like. Menthol is added in buccal tablet, syrup, and liquid preparations. The medicine has lung-heat clearing, cough-relieving, and phlegm expelling functions. The medicine can be used in medicine compositions used for treating diseases such as dry mouth and thirst, coughing and phlegm, and bronchitis coughing caused by wind heat invasion on lungs.
Diabetic ketoacidosis (DKA) remains the leading cause of morbidity and mortality in children with type 1 diabetes (T1D) and the incidence of T1D is increasing. A frequent complication in DKA management that is associated with in-hospital mortality and longer hospital stay is hyperglycemia; specifically rebound hyperglycemia (defined as a serum glucose greater than 180 mg/dL) within 12-24 hours after correction of the DKA. Rebound hyperglycemia increases the patient's risk of re-developing DKA. Few adult studies suggest that giving the long-acting insulin analog (glargine or Lantus®) early in the management of DKA (i.e. while still receiving intravenous insulin) can reduce rebound hyperglycemia without an increased risk of hypoglycemia and result in a smoother transition from intravenous insulin to subcutaneous insulin. This has not been well-studied in children to date. In this study the investigators want to determine whether giving glargine early in DKA management in children results in reduced rebound hyperglycemia without an increased risk in hypoglycemia. The investigators will do this by randomizing participants in DKA to either receive glargine early in the management of DKA (study group) or after resolution of DKA (control group); the latter is currently standard-of-care. Additionally, continuous glucose monitoring (CGM) systems have not been studied in a pediatric population with DKA. These devices measure blood sugar levels every 5 minutes and provide a great deal of information about blood sugar control patterns over many days. Not only will the use of CGM in this study provide meaningful information regarding blood sugar patterns during DKA treatment, it will also broaden the investigators knowledge of whether CGM is a feasible and accurate tool to use in this setting.
Using porous hollow fiber membranes, systems/methods for continuously synthesizing polymer-coated particles by anti-solvent crystallization are provided. The disclosed systems/methods provide for synthesis of polymer-coated drug particles/crystals from solutions of the polymer and the drug particles in suspension by exposing the solution to an anti-solvent through a porous hollow fiber device. A feed solution of a coating polymer with suspended drug particles can be exposed to an anti-solvent through hollow fiber pores, thereby causing the polymer to precipitate on and coat the drug particles. In addition, a feed solution of a coating polymer with drug in solution can be exposed to an anti-solvent through hollow fiber pores, thereby causing the drug to crystallize from the solution and the polymer to precipitate/coat the drug. Results indicate that a uniformly coated, free-flowing product may be developed in this advantageous porous hollow fiber anti-solvent crystallization method. The coated drug particles can be used for controlled release of the drug, and the molecule and the crystal structure are not affected by the process.
Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
BACKGROUND: Liver metastasis of CRC is still the main cause of poor prognosis in patients with CRC. Previous studies have suggested that serpin family C member 1(SERPINC1) is involved in the development of a variety of tumours, but its effect on colorectal cancer progression has been poorly elucidated.
METHODS: Based on the GEO database, this study identifies the core gene SERPINC1 associated with liver metastasis in CRC. We used transcriptomic data and immunohistochemical staining to explore the expression of SERPINC1 in normal, cancer, and liver metastases tissue from CRC patients. Clinical data obtained from our hospital were used to explore the impact of SERPINC1 on the prognosis of colon cancer patients. Mechanistically, the biological functions exerted by SERPINC1 in CRC were predicted by bioinformatics, and the results were validated by the results of the experiments in vitro. Cell lines with knockdown of SERPINC1 were performed a series assay such as trans well, CCK-8 and colony formation assay to explore the relationship between SERPINC1 and proliferation and metastasis of CRC cells. Finally, the effect of SERPINC1 on the sensitivity of colon cancer patients to immune checkpoint therapy was evaluated.
RESULTS: In CRC liver metastatic tissues, we found significantly high expression of SERPINC1. Briefly, 212 CRC cohorts showed that SERPINC1 was significantly associated with TNM stage and plasma CA19-9 and CEA in CRC patients. Univariate and multivariate Cox demonstrated that SERPINC1 was significantly associated with 5-year survival after radical surgery for colorectal cancer (p < 0.001). Bioinformatics predicted that SERPINC1 affects metastasis of colon cancer through epithelial-mesenchymal transition (EMT). Colony formation assay and CCK-8 assay showed that SERPINC1 promotes malignant proliferation of CRC cells, trans well assay showed that SERPINC1 promotes distant migratory behaviour of CRC cells and protein blotting assay showed that SERPINC1 may promote migration by promoting the TGF-β1-mediated EMT of CRC cells. In addition, several immunotherapy cohorts also reflected that the expression of SERPINC1 reduced the sensitivity of CRC patients to immune checkpoint therapy.
CONCLUSION: Our study identified SERPINC1 as a novel liver metastasis-associated gene in CRC. Targeting SERPINC1 may be a novel therapeutic strategy for patients with liver metastases from CRC.
OBJECTIVES: I. Determine the maximum tolerated dose and recommended phase II dose of lurtotecan liposome and cisplatin in patients with advanced solid tumors. II. Determine the toxicity profile, dose-limiting toxic effects, and the pharmacokinetics of this treatment regimen in this patient population. III. Determine any correlation between toxicity profile and pharmacokinetics of this treatment regimen in these patients. IV. Determine the objective tumor response to this treatment regimen in patients with measurable disease (previously untreated solid tumors) entered at the recommended phase II dose.

OUTLINE: This is an open-label, multicenter, dose-escalation study of lurtotecan liposome. Patients receive cisplatin IV over 1 hour followed by lurtotecan liposome IV over 30 minutes on days 1-3. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Once the total dose of cisplatin is reached, patients receive lurtotecan liposome alone. Patients achieving complete response (CR) continue therapy for 2 courses after documentation of confirmed CR. Patients achieving partial response (PR) continue therapy until progression or for 2 courses after documentation of stable PR. Patients with stable disease continue therapy for a maximum of 6 courses. Cohorts of 3-6 patients receive escalating doses of lurtotecan liposome until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 patients with previously untreated solid tumors are treated at the recommended phase II dose (1 dose below the MTD). Patients are followed at 4 weeks and then every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 20-25 patients will be accrued for this study within 12-15 months.
A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
PURPOSE:The titled excellent pharmaceutical prepared by dispersing a carrier powder in which a chemical is impregnated and absorbed in a porous layer, filling pores of the porous layer with a solvent capable of dissolving the chemical, and laminating the resultant porous layer to a backing member, and capable of controlling the release rate of the chemical. CONSTITUTION:A pharmaceutical for prolonged release of a chemical prepared by dispersing a powder 3, containing the chemical, e.g. an antiangina pectoris agent or anticonvulsant agent, and obtained by impregnating and absorbing the chemical uniformly in a powdery carrier layer 2, e.g. a silicone resin, polyvinyl acetate or collagen, filling pores of the porous layer 2 with a solvent 5, e.g. mineral oil or silicone oil, and laminating the resultant porous layer 2 to one surface of a backing member 1, e.g. cellulose acetate or polyamide. The resultant pharmaceutical has improved prolonged release properties of releasing the chemical at substantially a constant rate for a long term and keeping the concentration in blood of the chemical to be absorbed from the applied surface into the body substantially at a constant value.
PACU and ward providers caring for participants in the brief contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a brief summary of the patient's forecast risk of major adverse events.
Cardiovascular and Cerebrovascular Events

Use of CHCs increases the risk of cardiovascular events and cerebrovascular events, such as myocardial infarction and stroke. The risk of these events with CHC use is greater in females with concomitant risk factors: age 35 years and older, smoking, hypertension, dyslipidemia, diabetes, or obesity. The risk increases with increasing age and with increasing number of cigarettes smoked.

Venous Thromboembolism

Use of CHCs also increases the risk of VTE, such as deep vein thrombosis and pulmonary embolism. The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman-years. The VTE risk should be considered in the context of relevant subpopulations of females of reproductive potential who are not taking CHCs (ADVERSE REACTIONS).

Risk factors for VTE with CHC use include smoking, obesity, family history of VTE, and prolonged immobilization, in addition to other factors that contraindicate use of CHCs (see CONTRAINDICATIONS). The presence of multiple risk factors for VTE with CHC use may further increase the risk. The risk of VTE is highest during the first year of CHC use and when restarting hormonal contraception after a break of four weeks or longer. The risk of VTE returns to baseline approximately 3 months after CHC use is discontinued.

Postpartum Venous Thromboembolism

The risk of VTE is increased during the first six weeks postpartum. The risk is highest up to four weeks postpartum but remains higher than baseline until at least six weeks postpartum. The presence of multiple risk factors for VTE may further increase the risk. Obstetric complications may extend the elevated risk up to 12 weeks postpartum.
Alveolar recruitment maneuvers \[ARM\] repeated every 30 min after tracheal intubation and after any disconnection from the ventilator. PEEP was routinely set at 6 cm H2O. If it was in a state of Trendelenburg position or carbon dioxide pneumoperitoneum, PEEP was set at 8 cm H2O.
The present application relates to a serine protease for selectively degrading mucin and use thereof. The serine protease is serine protease EatA, the protein thereof comprises a passenger domain with serine protease EatA activity. The passenger domain has an amino acid sequence with at least 90% identity with SEQ ID NO. 2, and is preferably an amino acid sequence set forth in SEQ ID NO. 2. The serine protease EatA can selectively degrade mucin in disease-related mucus, and has relatively high and lasting stability.
Intussusception is the invagination of a segment of bowel into an adjacent segment resulting into an intestinal obstruction. It is the most common acquired cause of intestinal obstruction in children aged four months to two years with a peak of incidence between four and nine months of age. Etiology of intussusception is reported to be idiopathic in about 90% of cases and rarely is it associated with pathological lead points such as Meckel's diverticulum, appendix, solid bowel lesions, intestinal polyp, and intestinal lymphoma. It is an occlusive-strangulation type of intestinal obstruction, and all necessary measures should be taken early to ensure prompt diagnosis and treatment to avoid ischaemia and necrosis of bowel. The term comes from two Latin words, intus, which means "inside" and suscipere, which means "to receive". It has been reported in neonates and adults . The ancient Greeks, treated intestinal obstruction with enema or insufflations of air into the anus. Abdominal pain, vomiting and blood in stools are the classic triad and are uncommon and seen in less than one-third of the children affected. Cases often present with non-specific symptoms, including vomiting, pain, irritability, decreased appetite and lethargy, and this may render diagnosis of intussusception difficult. Abdominal ultrasound is considered the standard choice for its diagnosis. Non-surgical management with Pneumatic reduction (PR) by air, hydrostatic reduction by saline or contrast enema is the best procedure.Surgical management by exploratory laparotomy with simple reduction while some cases may require a bowel resection and reanastomosis for gangrenous bowel.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes a pharmaceutical composition that has effective amount of at least one phospholipid. Phospholipid can be presented by phosphatidyl-choline or sphingolipid. Composition can involve additionally up to 70% by mass of neutral lipid and therapeutically effective amount of cholanic acid or its salts. Neutral lipid can be presented by triglyceride or cholesterol ester. Cholanic acid or its salt is presented by bile acid or bile acid salt. Bile acid salt is taken among sodium cholate, sodium deoxycholate and sodium chenodeoxycholate. Method of treatment or prophylaxis of humans or animals with endotoxemia or neutralization of end toxins involves administration of the above indicated pharmaceutical composition that provides the level of phospholipid about up to 400 mg/kg of body mass of indicated human or animal. EFFECT: suppression of toxicity induced by end toxins, removal of end toxins from body in intoxication. 28 cl, 10 dwg, 5 tbl, 10 ex
PURPOSE:To provide the titled hybridoma having high specificity to Bacteroides gingivalis and high stability of the titer, by the fusion of a cell capable of producing the antibody of Bacteroides gingivalis with a myeloma cell. CONSTITUTION:(A) A cell capable of producing the antibody of Bacteroides gingivalis (BG) (e.g. the spleen cell separated from an animal such as mouse immunized with BG or its blood agglutinin, etc.) and (B) a myeloma cell (e.g. myeloma cell of mouse) are subjected to the cell fusion with a polyethylene glycol )having a molecular weight of about 1,000-6,000). The obtained reaction mixture is inoculated in an HAT medium to effect the exclusive proliferation of the hybridoma, and the objective, hybridoma capable of producing the monoclonal antibody of BG is separated from the medium e.g. by the ELISA process (enzyme-linked immuno-solvent assay), etc.
A vaccine, useful for protecting swine against transmissible gastroenteritis (TGE) infection, contains an antigen factor, sp. antigenic protein(SPA), which is at least partially lost in the recovery of TGE virus for use in vaccines. SPA is sol. in H20, has a buoyant d. of 1.02-1.03g/mL, and has a charge-neutralized electrophoretic mobility (Rf) of 1.84 relative to human serum albumin. It is admixed with a carrier or adjuvant suitable for veterinary adminstration. The SPA immmunogen is prepd. from TGE virus in a culture medium, subjected to centrifugation, the virus pptd. from the supernatant, the ppt. collected by centrifugation and dispersed in Eaglis min. essential medium, and the dispersion is subjected to rate-zonal centrifugation.
BACKGROUND: Although handgrip strength is associated with all-cause mortality in patients with chronic kidney disease (CKD), whether this relationship is dose-related is unknown. Therefore, we examined dose-response relationships between handgrip strength and all-cause mortality in CKD patients based on previous studies by meta-analysis.
METHODS: Data sources included three electronic databases (PubMed, Web of Science, and Embase) from inception through October 2023. The included cohort was a CKD population not limited to disease stage, and their handgrip strength was objectively measured. Two researchers independently screened studies, extracted data, and assessed the risk of bias. We utilized estimates of handgrip strength categories using robust-error meta-regression (REMR), pooled study-specific estimates, and established dose-response relationships. Outcomes of interest included only all-cause mortality.
RESULTS: A total of 18 studies with 4810 participants (aged 47-71 years) were included. REMR modeling showed a U-shaped trend of association between handgrip strength and all-cause mortality in patients with CKD. Higher handgrip strength values, from 10 kg to approximately 28 kg, were associated with lower mortality risk. After that, the risk of death increased slightly.
CONCLUSION: A U-shaped association exists between handgrip strength and all-cause mortality risk in CKD patients. Future studies with quantitative measurements for each CKD stage will help to determine precise relative risk estimates between handgrip strength and mortality risk in patients with different stages of CKD.